Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392469 | 0.91 | ACLY (0.40) | GPR119BRAFACLYUSP30EGLN2 | |
| SCHEMBL387927 | 0.84 | MAP2K1 (0.44) | MAP2K1BRAFKITMAP2K2 | |
| SCHEMBL391647 | 0.82 | MRGPRX1 (0.44) | MAP2K1BRAFKITMAP2K2 | |
| SCHEMBL13672516 | 0.82 | KIT (0.39) | MAP2K1BRAFKITMAP2K2 | |
| SCHEMBL391574 | 0.82 | MAP2K1 (0.53) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL391735 | 0.80 | KIT (0.48) | MAP2K1BRAFACLYKITMAP2K2 | |
| SCHEMBL392187 | 0.79 | ACLY (0.47) | MAP2K1BRAFACLYKITMAP2K2 | |
| SCHEMBL13672910 | 0.78 | KIT (0.42) | MAP2K1BRAFACLYKITMAP2K2 | |
| SCHEMBL392514 | 0.78 | MAP2K1 (0.43) | MAP2K1BRAFMAP2K2 | |
| SCHEMBL387833 | 0.78 | MAP2K1 (0.51) | MAP2K1BRAFMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8808742-B2 | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8808742-B2 | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8648116-B2 | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | ARDEA BIOSCIENCES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648116-B2 | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | ARDEA BIOSCIENCES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| EP-2184984-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | Ardea Biosciences, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009129246-A2 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009018233-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | GPR119 1642/4885MAP2K1 32/4885BRAF 1/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | GPR119 3550/4885MAP2K1 52/4885BRAF 1/4885 |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | GPR119 3550/4885MAP2K1 52/4885BRAF 1/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | GPR119 1665/4885MAP2K1 7/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.